Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure.
The effect of 1alpha-hydroxyvitamin D3 (1alpha-OHD3) on parathyroid function was studied in sixteen patients (ten on haemodialysis, six with chronic renal insufficiency) during treatment for 6--8 months. During treatment, a decrease in serum parathyroid hormone (s-PTH) and an increase in serum calcium were seen. An inverse linear correlation was found between serum calcium and logarithmic values of s-PTH in fifteen of sixteen patients, but the slopes of the regression lines varied considerably. This indicates that the suppression of parathyroid function seen during treatment with 1alpha-OHD3 is mediated by a rise in the serum concentration of calcium. For normalization of s-PTH, the serum concentration of calcium had to be above normal range in several patients, indicating a defect in calcium-mediated regulation of the secretion of parathyroid hormone. This abnormality was seen especially in long-term haemodialysed patients.
D000293:Adolescent; D000328:Adult; D002118:Calcium / Q000097:blood; D002648:Child; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010280:Parathyroid Glands / Q000187:drug effects* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D002118:Calcium